C
Corsera Health
AI-powered cardiovascular disease prediction and RNAi prevention
About Corsera Health
Corsera Health launched in September 2025 with a mission to predict and prevent atherosclerotic cardiovascular disease (ASCVD), aiming to extend healthspan. The Boston-based company was co-founded by biotech industry veterans John Maraganore, Ph.D., and Clive Meanwell, M.D., who serve as co-CEOs. Their collaboration marks their third significant venture, following successes with companies like Alnylam Pharmaceuticals and The Medicines Company, where they were instrumental in developing drugs such as Angiomax and Leqvio.
Read full description
The company is developing a dual-approach platform. The first component is 'Klotho Health,' a proprietary tool that uses causal AI to predict an individual's lifetime risk of cardiovascular disease. This tool aims to identify people who would benefit from earlier intervention to prevent cumulative cardiovascular damage. The second component is a preventive RNAi (RNA interference) medicine designed for once-annual administration. This therapeutic targets two key drivers of cardiovascular disease: PCSK9 to lower LDL cholesterol and angiotensinogen (AGT) to reduce blood pressure. Corsera Health expects its lead drug program to enter clinical trials by the end of 2025.
Corsera Health's business model focuses on a disruptive, consumer-oriented approach to preventive medicine, targeting a younger demographic interested in proactively managing their long-term health. By combining a predictive AI tool with an accessible, once-yearly treatment, the company aims for population-scale reach. The company launched with over $50 million in initial funding raised from its founders and insiders, choosing to develop its initial proof-of-concept in stealth before engaging traditional venture capital.
At a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 53.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Cardiology and cardiovascular, Chronic Disease, RNA, Longevity, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Corsera Health.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2026 | $80M | $320M | John Maraganore · Forbion Capital Partners · Population Health Partners | ↗ |
| EARLY VCOther financing | Sep 2025 | $50M | $200M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Corsera Health is 3.1K monthly website visits, down 56.9% over the last three months. Corsera Health's team grew 36.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Forbion Capital Partners
Population Health Partners
John Maraganore
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corsera Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corsera Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.